导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.01% | 1763/4773 |
| 近一周 | -2.26% | 1614/5462 |
| 近一月 | -4.34% | 2401/5421 |
| 近一季 | -7.88% | 2563/5209 |
| 近半年 | -6.40% | 3077/4920 |
| 近一年 | 7.31% | 1326/4366 |
| 近两年 | 62.67% | 1132/2954 |
| 近三年 | 26.31% | 1222/2253 |
| 成立以来 | 42.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.28% 981/4961 |
13.45% 2001/5312 |
- - |
- - |
| 2025 | 31.33% 1249/4813 |
2.18% 1447/3635 |
2.11% 1858/4076 |
24.71% 1442/4524 |
0.94% 1651/4813 |
| 2024 | -0.52% 2120/3463 |
-4.01% 1598/2808 |
-4.24% 1484/3014 |
11.04% 2563/3129 |
-2.54% 2124/3463 |
| 2023 | -7.68% 937/2656 |
6.85% 638/2280 |
-3.55% 827/2385 |
-5.75% 1366/2515 |
-4.95% 1219/2655 |
| 2022 | -23.77% 1167/2207 |
-13.12% 700/1919 |
1.70% 1434/2016 |
-12.77% 779/2113 |
-1.10% 1678/2208 |
| 2021 | 8.00% 487/1822 |
-6.70% 1030/1255 |
12.90% 302/1330 |
1.37% 452/1466 |
1.14% 999/1822 |
| 2020 | 38.07% 368/1250 |
-5.15% 402/1028 |
22.51% 204/1067 |
10.77% 514/1164 |
7.27% 721/1184 |
| 2019 | 26.80% 565/1092 |
25.33% 473/739 |
-8.94% 620/788 |
3.97% 224/850 |
6.85% 532/918 |
| 2018 | -31.19% 490/834 |
- - |
-13.94% 470/631 |
-6.55% 408/660 |
-10.93% 237/682 |
| 2017 | 10.55% 299/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证500量化增强C VS. 长安沪深300非周期A(740101) |